A significant number of interventional and observational clinical trial records, totaling more than 790, are associated with either KRAS itself or the pathway in which KRAS is involved. These meticulously designed interventional studies serve the purpose of evaluating potential treatments for cancers, including vaccines, monoclonal antibodies, and small molecules. Notably, there exist more than 22 small molecule inhibitors that exhibit varying degrees of specificity against distinct KRAS mutants.
